Patents by Inventor Anne M. Fourie

Anne M. Fourie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions of peptide inhibitors of Interleukin-23 receptor
    Patent number: 11939361
    Abstract: The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: March 26, 2024
    Assignees: Janssen Pharmaceutica NV, Protagonist Therapeutics, Inc.
    Inventors: Giustino Di Pretoro, Dajun Sun, Gopal Rajan, Geraldine Broeckx, Nathalie Mertens, Shu Li, Felix Lai, Mohammad Masjedizadeh, Anne M. Fourie, Beverly Knight, David Polidori, Santhosh Francis Neelamkavil, Nishit Modi, Ashok Bhandari, Xiaoli Cheng
  • METHODS OF IDENTIFYING MODULATORS OF THE IL-17 PATHWAY
    Publication number: 20230167497
    Abstract: Methods of identifying agents that modulate the interleukin-17 (IL-17) pathway are described. Said methods use detecting a level of granulocyte colony-stimulating factor (G-CSF) in a cell supernatant and/or detecting an expression level of one gene or a panel of genes of a cell treated with an agent. Also described are probes capable of detecting a gene or panel of genes and kits for identifying agents that modulate the IL-17 pathway.
    Type: Application
    Filed: April 28, 2021
    Publication date: June 1, 2023
    Inventors: Katherine Y. Blain, Aimee Rose de Leon-Tabaldo, Anne M. Fourie, Steven Goldberg, Xuejun Liu, Rosa Luna-Roman, Michael Angelo Rodriguez, Xiaohua Xue
  • PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORgT
    Publication number: 20220281823
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: May 5, 2022
    Publication date: September 8, 2022
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods, Anne M. Fourie, Xiaohua Xue
  • Pyridinyl pyrazoles as modulators of ROR?T
    Patent number: 11034658
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 15, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, Ronald L. Wolin, Anne M. Fourie, Xiaohua Xue
  • Phenyl substituted pyrazoles as modulators of ROR?t
    Patent number: 10975037
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: April 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Craig R. Woods, Ronald L. Wolin, William M. Jones, Anne M. Fourie, Xiaohua Xue
  • 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
    Patent number: 10975057
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: April 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Anne M. Fourie, Xiaohua Xue
  • 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORgT
    Publication number: 20190382373
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 19, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Anne M. Fourie, Xiaohua Xue
  • PYRIDINYL PYRAZOLES AS MODULATORS OF RORyT
    Publication number: 20190382350
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 19, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, Ronald L. Wolin, Anne M. Fourie, Xiaohua Xue
  • PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT
    Publication number: 20190382349
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 19, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Craig R. Woods, Ronald L. Wolin, William M. Jones, Anne M. Fourie, Xiaohua Xue
  • PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT
    Publication number: 20190382354
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 19, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods, Anne M. Fourie, Xiaohua Xue
  • Thiazoles as modulators of ROR?t
    Patent number: 10080744
    Abstract: The present invention comprises compounds of Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and {circle around (A)} are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: September 25, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • THIAZOLES AS MODULATORS OF RORyt
    Publication number: 20180064690
    Abstract: The present invention comprises compounds of Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 8, 2018
    Inventors: Steven Goldberg, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • Trifluoromethyl alcohols as modulators of ROR?t
    Patent number: 9850236
    Abstract: The present invention comprises compounds of Formula I. wherein: X, A1, A2, A3, A4, R1, R2, and R3 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 26, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Virginia Tanis, Olaf Kinzel, Christian Gege, Christoph Steeneck, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • Amide substituted thiazoles as modulators of RORyt
    Patent number: 9845319
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R5, A1, A2, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 19, 2017
    Assignee: Janssen Pharmaceutiuca NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Virginia Tanis, Maud Urbanski, Aihua Wang, David Kummer, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene Ahydrolase
    Patent number: 8399465
    Abstract: Compounds with two fused bicyclic heteroaryl moieties and their pharmaceutical compositions, and methods of using them as leukotriene A4 hydrolase (LTA4H) modulators and for the treatment of diseases, disorders and conditions mediated by LTA4H.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: March 19, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Genesis Bacani, Christa C. Chrovian, Wendy Eccles, Anne M. Fourie, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Alejandro Santillán, Jr., Virginia M. Tanis, John J. M. Wiener
  • Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
    Publication number: 20110190503
    Abstract: Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.
    Type: Application
    Filed: March 2, 2011
    Publication date: August 4, 2011
    Inventors: Genesis M. BACANI, Diego BROGGINI, Eugene Y. CHEUNG, Christa C. CHROVIAN, Xiaohu DENG, Anne M. FOURIE, Laurent GOMEZ, Cheryl A. GRICE, Aaron M. KEARNEY, Adrienne M. LANDRY-BAYLE, Alice LEE-DUTRA, Jimmy T. LIANG, Susanne LOCHNER, Neelakandha S. MANI, Alejandro SANTILLÁN, JR., Kathleen SAPPEY, Kia SEPASSI, Virginia M. TANIS, Alvah T. WICKBOLDT, John J. M. WIENER, Hartmut ZINSER
  • Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
    Publication number: 20110159563
    Abstract: Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.
    Type: Application
    Filed: March 2, 2011
    Publication date: June 30, 2011
    Inventors: Genesis M. Bacani, Diego Broggini, Eugene Y. Cheung, Christa C. Chrovian, Xiaohu Deng, Anne M. Fourie, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Jimmy T. Liang, Susanne Lochner, Neelakandha S. Mani, Alejandro Santillán, JR., Kathleen Sappey, Kia Sepassi, Virginia M. Tanis, Alvah T. Wickboldt, John J. M. Wiener, Hartmut Zinser
  • COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE
    Publication number: 20100292208
    Abstract: Compounds with two fused bicyclic heteroaryl moieties and their pharmaceutical compositions, and methods of using them as leukotriene A4 hydrolase (LTA4H) modulators and for the treatment of diseases, disorders and conditions mediated by LTA4H.
    Type: Application
    Filed: May 12, 2010
    Publication date: November 18, 2010
    Inventors: Genesis Bacani, Christa C. Chrovian, Wendy Eccles, Anne M. Fourie, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Alejandro Santillán, JR., Virginia M. Tanis, John J. M. Wiener
  • Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
    Publication number: 20090258854
    Abstract: Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.
    Type: Application
    Filed: April 9, 2009
    Publication date: October 15, 2009
    Inventors: Genesis M. Bacani, Diego Broggini, Eugene Y. Cheung, Christa C. Chrovian, Xiaohu Deng, Anne M. Fourie, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearny, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Jimmy T. Liang, Susanne Lochner, Neelakandha S. Mani, Alejandro Santillan, JR., Kathleen Sappey, Kia Sepassi, Virginia M. Tanis, Alvah T. Wickboldt, John J. M. Wiener, Hartmut Zinser
  • LTA4H modulators and uses thereof
    Publication number: 20080194630
    Abstract: Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.
    Type: Application
    Filed: February 14, 2008
    Publication date: August 14, 2008
    Inventors: William T. Barchuk, Paul J. Dunford, James P. Edwards, Anne M. Fourie, Lars Karlsson, Joanne M. Quan